SIGA Technologies - Monkeypox concern drives international TPOXX win
SIGA Technologies (SIGA) has announced receipt of $16m of international procurement orders in the European Union (EU) and the Asia-Pacific region (APAC) for oral TPOXX (tecovirimat) for short-term stockpiling and/or deployment against the monkeypox outbreak. To date in 2022, SIGA has received about $76m in international orders for oral TPOXX from 12 customers, and about $65m of those orders are expected to be delivered in 2022. The contract wins are evidence of SIGA’s continued penetration into the EU and APAC. We expect continued strong momentum for the company as demand for therapeutics such as TPOXX intensifies as countries focus on addressing the monkeypox outbreak. We maintain our valuation of $19.80 per SIGA share.SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.